BERKELEY, Calif., Sept. 10, 2018 /PRNewswire/ -- The following statement about today's U.S. Court of Appeals decision onUC's patent interference claim before the Patent Trial and Appeal Board may be attributed to Charles F. Robinson, Office of General Counsel, University of California Office of the President:
The court did not address the question of who invented the specific use of CRISPR-Cas9 in eukaryotic cells and emphasized that its decision was "not a ruling on the validity of either" Broad's or UC's claims. The decision thus does not preclude other proceedings, either in the USPTO or in the courts, by which UC may seek to establish that it is the actual inventor of use of the CRISPR-Cas9 system in eukaryotic cells.
Accordingly, we are currently evaluating our further legal options in the courts and/or the USPTO.
Lastly, we are pleased that the USPTO will continue to issue patents to UC for its foundational technology relating to the use of CRISPR-Cas9, including its use in any environment. As it has for 150 years, UC will translate this and its many research discoveries for the public good. UC has a policy of openly licensing technologies to non-profits and educational institutions and has licensed CRISPR-Cas9 technology so that it now is used by multiple companies currently working to accelerate breakthroughs in human therapies. Our commitment to develop and apply CRISPR-Cas9 for the betterment of human kind is unchanged by today's decision.
Media Contact: Jennifer Tong: (202) 748-1758
View original content:http://www.prnewswire.com/news-releases/university-of-california-responds-to-court-of-appeals-crispr-cas9-decision-vows-to-protect-groundbreaking-discovery-300710044.html
SOURCE University of California Office of the President
Subscribe to our Free Newsletters!